
Frontiers of Antibiotic Research

Edited by
Hamao Umezawa

Frontiers of Antibiotic Research

Edited by

Hamao Umezawa

Institute of Microbial Chemistry
Tokyo, Japan

1987



ACADEMIC PRESS, INC.

Harcourt Brace Jovanovich, Publishers

Tokyo Orlando San Diego New York

Austin Boston London Sydney Toronto

COPYRIGHT © 1987 by The Takeda Science Foundation
ALL RIGHTS RESERVED.

NO PART OF THIS PUBLICATION MAY BE REPRODUCED OR
TRANSMITTED IN ANY FORM OR BY ANY MEANS, ELECTRONIC
OR MECHANICAL, INCLUDING PHOTOCOPY, RECORDING, OR ANY
INFORMATION STORAGE AND RETRIEVAL SYSTEM, WITHOUT
PERMISSION IN WRITING FROM THE PUBLISHER.

ACADEMIC PRESS JAPAN, INC.
Ichibancho Central Bldg., 22-1 Ichibancho, Chiyoda-ku, Tokyo 102

United States Edition published by
ACADEMIC PRESS, INC.
Orlando, Florida 32887

United Kingdom Edition published by
ACADEMIC PRESS, INC. (LONDON) LTD.
24/28 Oval Road, London NW1 7DX

Library of Congress Cataloging-in-Publication Data
Frontiers of Antibiotic Research

Proceedings of the Fourth Takeda Science Foundation
Symposium on Bioscience, held
November 25-27, 1986, in Kyoto, Japan.

Includes index.

1. Beta lactam antibiotics—Congresses. I. Umezawa,
Hamao. [DNLM: 1. Antibiotics—congresses. 2. Antibiotics,
Lactam—congresses. QV 350 F935 1986]
RM666.B46F76 1987 615'.329 87-31838
ISBN 0-12-708370-7 (U.S. : alk. paper)

Printed in Japan
87 88 89 90 9 8 7 6 5 4 3 2 1

001896

Frontiers of
Antibiotic Research

Antibiotic Research

ACADEMIC PRESS RAPID MANUSCRIPT REPRODUCTION

Foreword

The Takeda Science Foundation was established in 1963 by the late Mr. Chobei Takeda VI with an endowment from Takeda Chemical Industries, Ltd. Since then, the Foundation has contributed to the advancement of science and technology, and other cultural affairs throughout the world as well as in Japan. This has been done by awarding prizes to recognize outstanding research achievements in medical science, giving grants to researchers engaged in science and technology, providing fellowships to medical scientists studying in Japan, and preserving reference books and materials on traditional Asian medical science, which are made available to the public at the "Kyoou Shooku" library.

In addition to the above activities, the Takeda Science Foundation holds International Symposia on Bioscience. The members of the Symposium Committee are: Setsuro Ebashi, M.D. (Professor Emeritus, University of Tokyo; Professor, National Institute of Physiological Sciences); Osamu Hayaishi, M.D. (Professor Emeritus, Kyoto University; President, Osaka Medical College); Tomoji Suzuki, Ph.D. (Professor Emeritus, Kyoto University); Hamao Umezawa, M.D. (Professor Emeritus, University of Tokyo; Director, Institute of Microbial Chemistry); and Yuichi Yamamura, M.D. (Professor Emeritus, Osaka University).

The first Takeda Science Foundation Symposium on Bioscience was held in 1982, and every Symposium has been very successful. The fourth Symposium entitled "Frontiers of Antibiotic Research", held in Kyoto from November 25th to 27th, 1986, was organized by Dr. Hamao Umezawa, the chairman. The proceedings of this Symposium were edited for publication by the Organizing Committee.

Regretfully, however, Dr. Hamao Umezawa who was so dedicated to the accomplishment of this Symposium, passed away on December 25th, 1986, just one month after the Symposium.

This Symposium proved to be a great success and has contributed to the progress of bioscience by providing a forum for international exchange of scientific knowledge and experience. I hope that together the Symposium and proceedings will be a tribute to Dr. Umezawa and to his brilliant research career and dedication to the field of antibiotics.

I would like to express my sincere gratitude to the members of the Symposium Committee for supervising the fourth Symposium, and to the members of the Organizing Committee for planning such a wonderful program and helping to make the symposium a success.

Einosuke Ohmura, Ph.D.
Chairman, the Board of Trustees
Takeda Science Foundation

Preface

Antibiotic research covers a wide range of fields from basic to clinical investigations. Professor Hamao Umezawa, the former Director of the Institute of Microbial Chemistry, in Tokyo, was a powerful leader in the field of antibiotic research due to his wide range of knowledge in all these fields. Because of this, he was asked by the Takeda Science Foundation to chair the organizing committee for the symposium, "Frontiers of Antibiotic Research", which was held on November 25th ~ 27th, 1986.

Before receiving this request, he had intended to organize a symposium on antibiotic research for the 25th anniversary of the Institute in 1987. With this in mind, he placed special emphasis on β -lactam antibiotics for the present symposium. The aim was to provide up-to-date information on the recent research on β -lactam and associated antibiotics, including action, resistance, pharmacokinetics, inhibitors of β -lactamase and cell wall synthesis, biosynthesis, chemical synthesis and computer-assisted drug designing.

The symposium was held in accordance with his plans and was a great success. The high caliber of the contributions from the invited speakers and participants is reflected in these Proceedings. We believe this book will be of benefit to all researchers in areas of antibiotic research.

Unfortunately, Professor Umezawa was unable to attend the symposium because of serious illness. He passed away on December 25th, 1986, a month after the symposium. The members of the Editorial Board have attempted to complete his job in keeping with his ideas.

MEMBERS OF THE ORGANIZING COMMITTEE & EDITORIAL BOARD.

Proceedings of the Fourth Takeda Foundation Symposium
on Bioscience — 1986
Frontiers of Antibiotic Research

Members of the Symposium Committee

Setsuro Ebashi
National Institute for Physiological Sciences

Osamu Hayaishi
Osaka Medical College

Tomoji Suzuki
kyoto University

Hamao Umezawa
Institute of Microbial Chemistry

Yuichi Yamamura
Osaka University

Members of the Organizing Committee & Editorial Board

Chairman
Hamao Umezawa
Institute of Microbial Chemistry

Secretary General
Yoshiro Okami
Institute of Microbial Chemistry

Akira Imada
Biology Laboratories, Central Research Division
Takeda Chemical Industries, Ltd.

Masaji Ohno
University of Tokyo

Kihachiro Shimizu
Tokyo Women's Medical College

Nobuo Tanaka
University of Tokyo

Morimasa Yagisawa
Japan Antibiotics Research Association

Contents

Foreword	ix
Preface	xi
I. Biosynthesis and Chemistry of β-Lactams	
Recent Studies on the Biosynthesis of Penicillins and Cephalosporins <i>Jack E. Baldwin</i>	3
Chemicoenzymatic Synthesis of β -Lactam Compounds <i>Masaji Ohno, Susumu Kobayashi, Masa-aki Kurihara, Harumi Kaga and Haruo Yamashita</i>	19
II. Action of Antibiotics on Bacteria	
Structure and Function of Penicillin-Binding Proteins <i>Michio Matsuhashi, Fumitoshi Ishino, Masaaki Wachi, Yoshiyasu Ito, Kuni-Hiro Ueda, Min Dong Song, Robert A. Nicholas, Jack L. Strominger, Kimiko Ubukata and Masatoshi Konno</i>	37
Morphological Response of <i>Staphylococcus aureus</i> to β -Lactams <i>Takeshi Nishino and Masako Otsuki</i>	55
Effects of Antibiotics on Bacterial Virulence <i>Victor Lorian and Jerome Ernst</i>	69
III. Resistance Mechanisms	
Mechanisms of Resistance in Gram-Negative Bacteria A) Resistance by β -Lactamases <i>Susumu Mitsuhashi</i>	95
Mechanisms of Resistance in Gram-Negative Bacteria B) The Role of Permeability Barrier <i>Hiroshi Nikaido</i>	107
IV. Inhibition of β-Lactamases	
Combination with β -Lactamase Inhibitors <i>Takeshi Yokota</i>	121

Mechanisms of β -lactamase Action and Inhibition

*S.J. Cartwright, I.E. Crompton, C. Little, P.J. Madgwick,
J. Monks, S.G. Waley, B.W. Cuthbert, G. Lowe, R. Bicknell,
A. Schäffer and D.S. Auld*

131

V. Recent Development of β -Lactam Antibiotics

Properties of Recent Penam Antibiotics

Keith R. L. Mansford

149

Synthesis and Biological Properties of Newer Cephem Antibiotics

*Walter Dürckheimer, Friedhelm Adam, Gerd Fischer and
Reiner Kirrstetter*

161

Recent Development of Oxacephem Antibiotics

*Wataru Nagata, Mitsuru Yoshioka, Teruji Tsuji,
Tsutomu Aoki, Yasuhiro Nishitani, Sadao Yamamoto,
Masayuki Narisada, Tadashi Yoshida, Shinzoh Matsuura
and Yoshihide Komatsu*

193

New Monobactams—Chemistry and Biology

W.H. Koster and D.P. Bonner

211

Design and Synthetic Strategies to Novel Penem Antibiotics

Giovanni Franceschi and Ettore Perrone

227

Total Synthetic Strategy and the Design of β -Lactam Antibiotics

*L.M. Fuentes, I. Shinkai, A. King, R. Purick, R.A. Reamer,
S.M. Schmitt, L. Cama and B.G. Christensen*

243

VI. Pharmacokinetics of β -Lactam Antibiotics

Intestinal Absorption of Beta-Lactam Antibiotics

Akira Tsuji

255

Importance of Pharmacokinetics and Pharmacodynamics

in Determining the Efficacy of β -Lactams

William A. Craig and Steven C. Ebert

269

Optimal Dosing Regimens of β -Lactam Antibiotics

Bennett Vogelmann

285

VII. New Cell Wall Synthesis Inhibitors

Lactivicin, A New Type of Antibiotic Having β -Lactam-Like Activity

Hisayoshi Okazaki

303

Teicoplanin, A New Clinically Effective Antibiotic

Giancarlo Lancini

313

VIII. Theoretical Drug Designing

Crystallographic Comparisons of Penicillin-Binding Enzymes and Studies of Antibiotic Binding <i>Judith A. Kelly, Jeffrey C. Boyington, Paul C. Moews, James R. Knox, Otto Dideberg, Paulette Charlier, Marc Libert, Jean-Pierre Wery, Colette Duez, Bernard Joris, Jean Dusart, Jean-Marie Frere and Jean-Marie Ghuysen</i>	327
Computer-Assisted Molecular Design Studies of β -Lactam Antibiotics <i>Donald B. Boyd</i>	339
Subject and Bacteria Index	357
Drug Index	363

I. Biosynthesis and Chemistry of β -Lactams

RECENT STUDIES ON THE BIOSYNTHESIS OF PENICILLINS AND CEPHALOSPORINS

Jack E Baldwin

The Dyson Perrins Laboratory
University of Oxford
Oxford

In the first part of this lecture I would like to review the earlier work we have carried out on the biosynthesis of penicillin since I believe that the nature of this step is crucial to understanding the subsequent conversion of penicillin into cephalosporin, which is the objective of our most recent studies.

We have described the discovery in *C. acremonium* of an enzyme, isopenicillin N synthase (IPNS), which catalyses the conversion of tripeptide 1 into isopenicillin N 2, concomitant with the reduction of one molecule of dioxygen, fig.1 (1-2). Only those hydrogen atoms circled in this




Fig1

figure are removed from the substrate (3) and labelling studies have shown that that both new bonds, C-N and C-S are formed with retention of configuration (4-5). Thus the enzyme IPNS is acting as a desaturase ie removing

hydrogen from the substrate to form the ring structures of the product. This enzyme was purified in Oxford in collaboration with Professor Sir Edward Abraham in the William Dunn School, and an N-terminal sequence determined (6) and the gene isolated and sequenced by use of DNA probes based on the N-terminal sequence (7). The gene corresponds to an enzyme of M_r 38,000 containing two cysteines. No unusual cofactors appear to be involved but the enzyme is associated with iron and preliminary studies indicate a ratio of 1 atom of iron/mole enzyme. Ascorbate is essential to maintain enzyme activity. The gene has been cloned into a strain of *E. coli* and the expressed recombinant enzyme (ca 20% of cell protein) behaves in all respects identically to the natural fungal enzyme. Studies of the kinetic isotope effects of deuterium substitution into precursor 1 have been interpreted on the basis of a two step mechanism involving first loss of the β -cysteinyl hydrogen, followed by loss of the β -valinyl hydrogen. These studies also indicate that no enzyme free intermediate is involved. Consequently we believe that the simplest explanation of the isotope effects is that an enzyme-bound monocyclic lactam 3 is the intermediate, fig. 2 (8). In




fig 2

an alternative approach to the mechanism we have made an extensive investigation on the effects of structural modification to the natural substrate 1. The α -aminoadipyl moiety can be replaced with a six carbon chain terminating in a carboxyl group and still give relatively high rates of conversion (9). It is possible to make penicillin V and penicillin G from the corresponding dipeptides but the rates of conversion, in the absence of the carboxyl group, are very low (10). The cysteinyl moiety can be changed and yet still permit penicillin synthesis by the substitution of methyl groups for α - and β (pro-R) hydrogen atoms but the β -(pro-S), site will not tolerate substitution, since this is the hydrogen

normally removed in the enzymic step, fig. 3. Structural




fig 3

variation of the valine portion has led to some very interesting and surprising results. Thus the α -aminobutyrate analogue was found to give simultaneously three products, two penicillins and a cepham in the ratios shown, fig.4 (11). Intriguingly a group at ICI have found




fig 4

the two major products, as their D- α -aminoadipyl derivatives, in certain *Streptomyces* (12). Even more unusual was the finding that when the β -hydrogens of the aminobutyrate moiety were stereospecifically replaced by deuterium both the 3R and 3S monodeuterated peptides were